Abstract:Among the best-established causal risk factors for cardiovascular disease is the blood concentration of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), an antagonist to the LDL receptor, has emerged as a promising therapeutic target for the prevention of coronary heart disease. Current PCSK9 inhibitors are administered via subcutaneous injection, and their effects are short-lived. An alternative “one-and-done” strategy using genome editing to disrupt PCSK9 at the DNA level has been demonstrated in preclinical animal models, including non-human primates. However, concerns about the permanence and irreversibility of the genomic changes have been raised and might limit the acceptance of the therapies. Recently, a set of CRISPR-based epigenome editing tools, CRISPRoff and CRISPRon, were reported to regulate gene expression via site-directed methylation and demethylation of gene promoters, respectively. We hypothesized that these epigenome editing tools could durably and reversibly induce methylation changes in the PCSK9 promoter and thereby modulate its expression. We first screened CRISPRoff guide RNAs (gRNAs) targeting the PCSK9 promoter, individually and in dual combinations, for their ability to reduce PCSK9 expression in the human HuH-7 hepatoma cell line. We then performed long-term experiments with the lead candidate gRNAs. We found that these CRISPRoff gRNAs induced profound increases in methylation at CpG dinucleotides in the PCSK9 promoter, with up to 80% decreases in PCSK9 expression. These methylation increases and gene expression decreases have endured through >56 cell divisions so far, with only mild attenuation over time. Using the same gRNAs with CRISPRon in cells previously treated with CRISPRoff, we observed moderate decreases in methylation and increases in PCSK9 expression. Having established these effects in vitro , we are similarly assessing the durability and reversibility of epigenome editing using the lead gRNAs in a PCSK9 -humanized mouse model. Overall, this work provides a proof of concept of precise gene regulation via methylation and demethylation and suggests a potential new therapeutic approach for protection against coronary heart disease.

Construction of Small Hair RNA Lentiviral Vectors Targeting PCSK9 Gene and Its Silent Effects on PCSK9 Gene

Construction and identification of vector against Kir6.2 gene expression in hepatoma cells by short interfering RNAs

[Construction of Shrna Expression Vector Silencing Kir6.2 Gene and to Study Its Influence on the Proliferation and Invasion of HepG2 Cells].

BC047440 silencing in HepG2 cells mediated by lentiviral vector

Efficient Inhibition of Human Cytomegalovirus DNA Polymerase Expression by Small Hairpin RNA in Vitro

Lentiviral-Mediated Silencing of Farnesyl Pyrophosphate Synthase Through RNA Interference in Mice

Efficient Inhibition of Human Cytomegalovirus UL122 Gene Expression in Cell by Small Interfering RNAs

Construction of a lentiviral RNA interference system targeting heparanase based on miR30 and its silencing effect]

Construction of the recombinant adenovirus mediated short hairpin RNA to silence Polo-like kinase 1 and its biomedical application

Construction and expression of adenovirus vector of shRNA against SIK2 in in 3T3-L1 adipocytes

Construction of Targeting-Skp2 Shrna Plasmids and Observation of Their Inhibitory Effect on Tca8113 Cells

PCSK9 Inhibition: From Current Advances to Evolving Future

Construction of shRNA Lentiviral Vector Targeting Mice IL-35 Gene and Identification of RNAi Efficiency

Three New Shrna Expression Vectors Targeting the CYP3A4 Coding Sequence to Inhibit Its Expression

Triple‐Targeting Delivery of CRISPR/Cas9 to Reduce the Risk of Cardiovascular Diseases

Inhibition of HBV Core Antigen Gene Expression in Human Embryonic Kidney Cell Line AD293 by Plasmid-Based RNAi

A Method for Detecting and Preventing Negative RNA Interference in Preparation of Lentiviral Vectors for Sirna Delivery

Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9

Abstract 125: Reversible Epigenome Editing Of PCSK9 As A Therapeutic Strategy

Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.

Construction of shRNA expression plasmids targeting the Pyk2 gene and their expression in Lovo cells